In this issue:
Obinutuzumab + CHOP in treatment-naïve DLBCL
Higher dose rituximab improves DLBCL outcomes in older men?
Brentuximab vedotin enables curative SCT
CML survival influenced more by non-CML factors vs therapy
A position statement on haploidentical HSCT for adult AML
‘Real-world’ efficacy data for TKIs in CML
SC vs IV rituximab + CHOP in first-line DLBCL
CUDC-907: promising anti-tumour activity in DLBCL
Patient-level analysis of outcomes for refractory DLBCL
Please login below to download this issue (PDF)